Effectiveness and safety of Ustekinumab for the treatment of Crohn’s disease in real-life experiences: a meta-analysis of observational studies

References

• Macaluso FS, Fries W, Privitera AC, et al. A propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn’s disease: real-life data from the Sicilian network for inflammatory bowel disease (SN-IBD). J Crohns Colitis. 2018 Oct 6. Epub ahead of print. DOI:10.1093/ecco-jcc/jjy156.
   Web of Science ®Google Scholar
• Macaluso FS, Orlando R, Fries W, et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases. Dig Liver Dis. 2018;50:675–681.
   PubMedGoogle Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199–209.
   PubMed Web of Science ®Google Scholar
• Macaluso FS, Orlando A, Cottone M. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn’s disease. Expert Opin Biol Ther. 2018 Dec 20. Epub ahead of print. DOI:10.1080/14712598.2019.1561850
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 2008;135:1130–1141.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148–1158.
   PubMed Web of Science ®Google Scholar
• Papp K, Gottlieb AB, Naldi L, et al. Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol. 2015;14:706–714.
   PubMed Web of Science ®Google Scholar
• Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology a proposal for reporting. JAMA. 2000;283:2008–2012.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
   PubMed Web of Science ®Google Scholar
• Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohn’s Disease: the Spanish experience in a large multicentre open-label cohort. Inflamm Bowel Dis. 2016;22:1662–1669.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250.
   PubMed Web of Science ®Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s Disease. Clin Gastroenterol Hepatol. 2017;15:1427–1434.
   PubMed Web of Science ®Google Scholar
• Greenup AJ, Rosenfeld G, Bressler B. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017;52:1354–1359.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
   PubMed Web of Science ®Google Scholar
• Rowan CR, Keegan D, Byrne K, et al. Subcutaneous rather than intravenous ustekinumab induction is associated with comparable circulating drug levels and early clinical response: a pilot study. Aliment Pharmacol Ther. 2018;48:333–339.
   PubMed Web of Science ®Google Scholar
• Saman S, Goetz M, Wendler J, et al. Ustekinumab is effective in biological refractory Crohn’s disease patients-regardless of approval study selection criteria. Intest Res. 2019;17:340–348.
   PubMed Web of Science ®Google Scholar
• Iborra M, Beltrán B, Fernández-Clotet A, et al. Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn’s disease: results from the ENEIDA registry. Aliment Pharmacol Ther. 2019;50:278–288.
   PubMed Web of Science ®Google Scholar
• Liefferinckx C, Verstockt B, Gils A, et al. Long-term clinical effectiveness of ustekinumab in patients with crohn’s disease who failed biologic therapies: a national cohort study. J Crohns Colitis. 2019;13:1401–1409.
   PubMed Web of Science ®Google Scholar
• Verstockt B, Dreesen E, Noman M, et al. Ustekinumab exposure-outcome analysis in crohn’s disease only in part explains limited endoscopic remission rates. J Crohns Colitis. 2019;13:864–872.
   PubMed Web of Science ®Google Scholar
• Biemans VBC, van der Meulen-de Jong AE, van der Woude CJ, et al. Ustekinumab for Crohn’s disease: results of the ICC Registry, a nationwide prospective observational cohort study. J Crohns Colitis. 2019 Jun 14:pii: jjz119. Epub ahead of print. DOI: 10.1093/ecco-jcc/jjz119
   Web of Science ®Google Scholar
• Eberl A, Hallinen T, Af Björkesten CG, et al. Ustekinumab for Crohn’s disease: a nationwide real-life cohort study from Finland (FINUSTE). Scand J Gastroenterol. 2019;54:718–725.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Appendix 4. Quality assessment for Case series. [Updated 2019 Jan]. Available from: https://www.nice.org.uk/guidance/cg3/documents/appendix-4-quality-of-case-series-form2
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Viechtbauer W. Conducting meta-analyses in R with the metafor package. J Stat Software. 2010;36:1–48.
   Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016. URL https://www.R-project.org/
   Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab in inducing endoscopic healing in patients with Crohn’s Disease. Gastroenterology. 2018;155:1045–1058.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324.
   PubMed Web of Science ®Google Scholar